Stemtech Corporation Announces Appointment of Two Additional Board Members
Stemtech Corporation (OTC: GNTW) has appointed two new Board members, Darryl Green and Benjamin Kaplan, expanding its Board to five directors. Green, a veteran in the health and wellness sector, has over 30 years of experience, including a leadership role at GNC Holdings where he contributed to a significant market cap increase. Kaplan, an entrepreneur and investor in health and wellness, is currently CEO of Ehave, Inc. Chairman Charles Arnold expressed confidence that their expertise will help Stemtech scale operations effectively.
- Appointment of Darryl Green and Benjamin Kaplan adds valuable industry experience to the Board.
- Green's previous success in driving GNC's market cap growth from $1 billion to over $3.7 billion.
- Kaplan's entrepreneurial experience is expected to strengthen strategic operations.
- None.
MIRAMAR, Fla., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Stemtech Corporation (“Stemtech”) (OTC: GNTW), a leading nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that it has appointed two new Board members, Darryl Green and Benjamin Kaplan, bringing the total number of Stemtech Directors to five.
Mr. Green is a 30-year veteran of the health, wellness and supplements industry with deep domain expertise, and served as President of Domestic and International Franchising for GNC Holdings, Inc. He spent more than 30 years with GNC, which included 20 years of corporate and franchise executive positions, and over 10 years of various field positions, encompassing all facets of retail operations across the United States. In 2011, he was part of the team that led the number one IPO of the year, helping the company to raise
Mr. Kaplan has been a successful entrepreneur and investor for over 20 years, with a particular focus on health, wellness and pharmaceutical companies. He currently serves as the CEO of Ehave, Inc., a leader in digital therapeutics delivering evidence-based therapeutic interventions to patients.
“We are proud to welcome Darryl Green and Benjamin Kaplan to the Board,” said Charles Arnold, Chairman and CEO of Stemtech. “Both Darryl and Ben were early investors in Stemtech, and add tremendous value to the team. Darryl Green’s extensive, in-depth background in senior executive roles in the health, wellness and supplements industry is a strategic asset to the Company that we believe will assist us in successfully scaling our operations.”
The Stemtech board now consists of Charles Arnold, Chairman and CEO, John W. Meyer COO, John “JT” Thatch, Darryl Green and Benjamin Kaplan.
About Stemtech Corporation
Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and in select international markets. The Company’s patented formulas help the release, circulation and migration of the body’s adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem™, DermaStem®, DermaStem Lift, OraStem® (Oral Health Care), and D-Fuze™. Its products are all-natural and plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplemental Health and Education Act (DSHEA). For more information, please visit www.stemtech.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q filed July 13th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
For Further Information, Contact:
Investors: Frank J. Pena, 908-675-0581, fpena@stemtech.com
FAQ
Who are the new Board members appointed by Stemtech Corporation?
What is the significance of Darryl Green's appointment to Stemtech Corporation?
How does Benjamin Kaplan contribute to Stemtech Corporation's Board?
What is the current composition of Stemtech Corporation's Board of Directors?
What impact could the new Board appointments have on Stemtech Corporation?
